Clinical trials: Lung Neoplasms/Diagnosis
Esophagus Cancer, Lung Cancer
Imaging Study Compare 4DCT Image
The goal of this clinical research study is to learn about ways to possibly reduce scanning errors when using 4-dimensional computed tomography (4D CT) scans to check lung function in patients with esophageal or lung cancer.
- Trial name
- NCT01626001
- Testing
- 4D CT scans
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Pilot Phase II Study The primary objective for this study is: To explore the usefulness of [F-18]RGD-K5 PET/CT to predict efficacy or early response to Avastin® (the anti-angiogenesis drug) plus chemotherapy treatment before…
- Conditions
- Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer, Non-squamous Non-small Cell Lung Cancer
- Trial name
- K5-101 (NCT00988936)
- Testing
- [F-18]RGD-K5
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Siemens Molecular Imaging
Pulmonary Embolism, Deep Vein Thrombosis
Multi-Center Human Alert Trial to Prevent DVT and PE
To evaluate physician response to human alerts that inform the clinician that his/her patient may be eligible for thromboprophylaxis.
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
- Trial name
- NCT00409136
- Testing
- Human Alert
- Where
- 26 sites in United States
- Volunteers
- 2,496 people
- Sponsor
- Brigham and Women's Hospital
Esophagus Cancer, Lung Cancer
Feasibility Study of Navigated Endoscopy for the Placement of High Dose Rate Brachytherapy Applicators in the Esophagus and Lung
The scope of this clinical trial is to assess the clinical feasibility of this procedure, optimize the protocol and perform an initial comparison of the positional accuracy of navigated endoscopy and applicator insertion versus…
- Trial name
- NCT03051802
- Testing
- Navigated Endoscopy
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Lung Cancer
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
Our objective is to assess whether the use of high flow nasal cannula (Vapotherm, Exeter, NH) with monitored anesthesia care (MAC) during an endobronchial ultrasound (EBUS) bronchoscopy procedure will lead to less procedure…
- Trial name
- NCT05203328
- Testing
- Vapotherm, Regular nasal canula
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- The Cooper Health System
Lung Cancer
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00016367
- Testing
- Trastuzumab, Cisplatin, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC)
NSCLC patients often have cerebral metastasis : 10% at diagnosis and 40% during disease management. Neurosurgery is not indicated in the majority of cases because of presence of several lesions in the brain, failure of primary…
- Trial name
- GFPC 07-01 (NCT00744900)
- Testing
- Pemetrexed, cisplatin
- Where
- 25 sites in France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Brest
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IV Without EGFR/ALK Mutation
Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer
This study includes patients with advanced non-small cell lung cancer (NSCLC) - either unresectable stage III or stage IV adenocarcinoma without actionable driver mutations - who are treated with pembrolizumab in combination with…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IV Without EGFR/ALK Mutation, NSCLC Adenocarcinoma
- Trial name
- NCT06951399
- Testing
- Pembrolizumab (KEYTRUDA®)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rabin Medical Center
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Non Small Cell Lung Cancer
Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
This is a single arm, one center, phaseⅡ study evaluating efficacy and safety of erlotinib as neoadjuvent treatment in patients with EBUS confirmed stage ⅢA N2 NSCLC with activating EGFR mutation in exon 19 or 21.
- Trial name
- ML25444 (NCT01217619)
- Testing
- erlotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Baohui Han
Non-small-cell Lung Cancer
E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to determined the maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 administered continually twice daily in combination with…
- Trial name
- NCT00832819
- Testing
- E7080, Paclitaxel, Carboplatin
- Where
- 3 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Eisai Co., Ltd.
Carcinoma, Small Cell Lung
Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with atezolizumab in participants who have…
- Trial name
- Match (NCT04622228)
- Testing
- Atezolizumab, Cisplatin, Carboplatin
- Where
- 8 sites in China
- Volunteers
- 56 people
- Sponsor
- Hoffmann-La Roche
Lung Neoplasm
Reader Study of DeltaView™ Chest Radiograph Software
A new software product takes two chest radiographs, aligns them, and then subtracts one image from the other. The resulting image represents an image showing any differences between them.
- Trial name
- NCT01261507
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Georgetown University
Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and…
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
- Trial name
- NCT01737502
- Testing
- Auranofin, Sirolimus, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Lung Cancer
Application of SERS Technology Based Intraoperative Navigation System in Lung Cancer
This study aims to explore the application of Surface-enhanced Raman Scatting (SERS) technology in lung cancer surgery and clarify its mechanism through multi-omics mass spectrometry platform, and then further prove the clinical…
- Trial name
- NCT05881057
- Volunteers
- 200 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Neoplasms
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.
- Trial name
- NCT02588612
- Testing
- letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
The purpose of this study was to evaluate the major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR of…
- Trial name
- CANOPY-N (NCT03968419)
- Testing
- Canakinumab, Pembrolizumab
- Where
- 29 sites in United States, Belgium and 10 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Nodules, Early Detection of Cancer
Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
This is a prospective, multicenter observational cohort study for patients with lung nodules suspicious for early-stage lung cancer.
- Conditions
- Pulmonary Nodules, Early Detection of Cancer, Lung Neoplasms
- Trial name
- NCT07882628
- Where
- 8 sites in China
- Volunteers
- 1,050 people
- Sponsor
- Beijing Chao Yang Hospital
Non-Small-Cell Lung Carcinoma
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70…
- Trial name
- NCT00137800
- Testing
- OSI-774 (Tarceva)
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Depression, Anxiety
Effects of MSC Intervention on the Dyadic Mental Health of Lung Cancer Patients and Their Caregivers
The incidence and mortality of lung cancer ranks first among cancers in the world, and the five-year survival rate of lung cancer patients is only 15% to 30%.
- Trial name
- NCT04795700
- Testing
- MSC intervention
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Central South University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.